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6/j.bIncreased plasma concentrations of YKL-40, also called chitinase-3-like-1 protein (CHI3L1), have been cor-
related with disease severity in a variety of malignant and inflammatory diseases. The objective of the current
study was to assess pretransplant recipient and donor CHI3L1 polymorphisms and plasma YKL-40 concen-
trations as prognostic biomarkers in a cohort of 149 patients treated with hematopoietic cell transplantation
(HCT) after nonmyeloablative conditioning for hematologic malignancies. Recipients with pretransplant
YKL-40 concentrations above the age-adjusted 95th percentile (high) had higher relapse-related mortality
(33% versus 18%, P 5 .04; hazard ratio (HR) 5 4.41, P 5 .01), lower progression-free survival (38% versus
64%, P\.01; HR 5 2.84, P 5 .01), and overall survival (42% versus 69%, P 5 .01; HR 5 3.09, P 5 .01). Re-
cipients transplanted with donors with high YKL-40 concentrations had an increased probability and risk of
grade 2-4 acute graft-versus-host disease (aGVHD) (93% versus 62%, P\.01; HR 5 2.25, P 5 .02). CHI3L1
polymorphisms were associated with plasma YKL-40 concentrations, but not with clinical outcomes. In con-
clusion, our study suggests that plasma YKL-40 could function as a biomarker for relapse risk and treatment-
related toxicity, and possibly as a tool complementing clinical risk scores such as the HCT comorbidity index.
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versus-host disease, PrognosisINTRODUCTION
With the introduction of reduced-intensity condi-
tioning (RIC), allogeneic hematopoietic cell transplanta-
tion (HCT) has become a curative treatment option for
a variety of malignant hematologic diseases in older and
medically infirm patients. However, complications such
as graft-versus-host disease (GVHD), infections, andboratory of Molecular Medicine, Department of
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In the older andmedically infirm patient population that
is only eligible for RIC, prognostic factors such as the
Kahl score [1] or the HCT comorbidity index [2,3]
have proven useful in predicting the risk of relapse and
treatment-related mortality (TRM). However, to appro-
priately balance the likelihood of disease control against
the risk of debilitating complications, still more accurate
pretransplant tools are needed to predict outcome. In-
flammatorybiomarkers serve asprognostic tools in a vari-
ety of disease settings, and in allogeneicHCT it has been
shown that rising or increased concentrations of markers
such as C reactive protein (CRP), interleukin (IL)-6, and
tumornecrosis factor (TNF)-a in theposttransplantation
period are predictive of treatment-related toxicity [4-8].
The predictive value of inflammatory biomarkers in the
pretransplant period is less well investigated. However,
increased pretransplant concentrations of CRP have
been shown to associate with increased incidence of
infectious complications, acute GVHD (aGVHD), and
TRM [9,10].
YKL-40, also called chitinase-3-like-1 protein
(CHI3L1), is a phylogenetically conserved heparin-,
chitin-, and collagen-binding member of the family
of mammalian chitinase-like proteins. It is regarded1299
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tions of YKL-40 have been observed in a variety of in-
flammatory diseases of infectious and noninfectious
etiology (reviewed by Johansen et al. [11]). In cancer,
elevated YKL-40 concentrations have been associated
with advanced disease [12], and in a large prospective
study of a general Danish population cohort, high
YKL-40 concentrations were predictive of the devel-
opment of gastrointestinal cancer in subjects without
known cancer [13]. YKL-40 is secreted by cancer cells
[14], vascular smooth muscle cells [15], connective
tissue cells [16,17], neutrophile granulocytes, and
macrophages [18-20], and although its exact
biological function is unknown, it is involved in of
cell proliferation and differentiation [21], angiogenesis
[22], matrix remodeling, and inflammation [14]. Secre-
tion of YKL-40 is induced by interferon (INF)-g [23]
and IL-6 (J.S.J., unpublished results), and it has been
suggested that it is involved, as an opsonin, in activat-
ing innate immune responses [14,24]. In a murine
knockout model, the YKL-40 analog Brp-39 has
been shown to be of importance in establishing Th2
polarized immune responses and augmenting the
accumulation of macrophages, dendritic cells, and
T cells by inhibiting apoptosis [25]. Compared to
another acute-phase reactant such as CRP, YKL-40
has a different temporospatial secretion profile and
therefore only a weak correlation to CRP [26-29].
Furthermore, YKL-40 may reflect disease activity
more accurately, as it originates from cancer cells
and inflammatory cells directly involved in the patho-
logical process, whereas CRP is secreted by hepato-
cytes as a response to IL-6 [14].
Because of the ability of YKL-40 to predict survival
and disease severity across a large variety of cancers
and inflammatory disorders, and because of its involve-
ment in processes central to oncogenesis and inflam-
mation, we hypothesized that pretransplant YKL-40
concentration orCHI3L1 genotype could be a valuable
prognostic marker in the setting of nonmyeloablative
conditioned allogeneic HCT, and that both could cap-
ture the inherent risk of relapse associated with cancer
and comorbid conditions.METHODS
Study Cohorts
The study cohort consisted of 149 consecutive recip-
ients treatedwith allogeneicHCTfollowing nonmyeloa-
blative conditioning for hematologic malignancies
(acute myeloid leukemia/myelodysplastic syndrome
[AML/MDS], n 5 54 [36%]; chronic myeloid leukemia
[CML], n 5 3 [2%]; chronic lymphocytic leukemia
(CLL), n 5 21 [14%]; non-Hodgkin lymphoma
[NHL], n 5 16 [11%]; and multiple myeloma [MM],
n 5 16 [11%]) between March 2000 and July 2007, atthe bone marrow transplantation unit at Rigshospitalet,
Copenhagen, Denmark. Sixty-seven (45%) of the recipi-
entswere in complete remission (CR), and82 (55%)were
not in complete remission. When stratified according to
risk of relapse after allogeneic HCT [1], 32 (21%) had
low risk and 72 (48%) and 45 (30%) had standard and
high risk, respectively. For related donors (n 5 86
[58%]), donor selection was based on serologic typing
for HLA-A and -B and on molecular typing for HLA-
C, -DRB1, and DQB1. For unrelated donors (n 5 63
[42%]), donor selection was based on molecular typing
for HLA-A, -B, -C, -DRB1, and -DQB1. When avail-
able, HLA-identical siblings were preferred to matched
unrelated donors (in 11 unrelated donors, a single allele
mismatch was present), and cytomegalovirus serostatus
(cytomegalovirus [CMV]-negative recipient and donor,
n5 31 [21%]; other combinations, n5 118 [79%]) and
gender mismatch (male recipient/female donor, n 5 34
[23%]); other combinations n 5 115 (77%) were taken
into account when possible. All recipients received trans-
plants of peripheral blood stem cells (PBSC) after condi-
tioningwith fludarabine 30mg/m2 for 3 days and 2Gy of
total-body irradiation (TBI), except for 2 recipients who
were conditionedwith 2-GyTBI only.Donor treatment,
conditioning regimen, and supportive care have been
described previously [30]. Acute GVHD and chronic
GVHD(cGVHD)were diagnosed according to standard
criteria [31].
Bloodsamples forplasmameasurementandDNAex-
traction were obtained from recipients during pretrans-
plantation workup, which was scheduled approximately
2 to 3 weeks prior to conditioning. Recipients were not
treated with chemotherapy in the time period between
pretransplant workup and conditioning. However, some
recipients could be recovering from chemotherapy-
induced nadirs. From related donors and domestic
unrelated donors, samples were obtained during pre-
leukapheresis workup. Plasma samples were obtained
before treatment with granulocyte colony-stimulating
factor (G-CSF) was begun. For international donors,
plasma samples were not available. DNA was available
from all recipients and donors, and plasma was available
from 112 (75%) recipients and 92 (62%) donors.
For the purpose of comparing the distribution of
genotypes in the recipient and donor cohorts to the
general population, a cohort of 100 Danish Caucasian
healthy blood donors served as controls. DNA and
plasma samples were available from all control subjects.
Informed consent was obtained from all recipients,
donors, and controls, and the local ethics committee
approved the study.Genotyping
DNA from samples was extracted using the Prom-
egaMaxwell 16 bloodDNAkit (PromegaCorporation,
Madison, WI). The control cohort was genotyped
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(rs4950929), and SNP4 (rs4950928), whereas recipient
and donor cohorts were genotyped only for SNP1, -2,
and -4. Polymerase chain reaction (PCR) amplification
was performed as previously described [32] in reaction
volumes of 12 mL or 24 mL, prior to genotyping by
direct Sanger sequencing or pyrosequencing, respec-
tively. Pyrosequencing was performed, according to
the manufacturer’s protocol, on a PSQ 96A pyrose-
quencing platform (Biotage AB, Uppsala, Sweden) fol-
lowing Streptavidin Sepharose High-Performance
Beads (GE Healthcare Bio-Sciences Corp., Piscaway,
NJ) and Vacuum Prep Tool (Biotage AB) purification.
Direct Sanger sequencing was performed using ABI
BigDye Terminator v1.1 and v3.0 Cycle Sequencing
Kit on an ABI Prism 3130 Genetic Analyzer (Applied
Biosystems, Bedford, MA) using forward PCR primers
and purification by EtOH precipitation as previously
described [32]. All primers for PCR and pyrosequenc-
ing were produced by DNATechnology A/S, Risskov,
Denmark, and are shown in Supplementary Table S1.
YKL-40 Plasma Analyses
Plasma was prepared from EDTA-anticoagulated
blood within 8 hours of sampling and stored at280C
until YKL-40 analysis. YKL-40 concentrations are sta-
ble at room temperature in EDTA-anticoagulated
blood for up to 8 hours [33]. Plasma concentrations of
YKL-40weredetermined induplicates using a commer-
cial sandwich-type enzyme-linked immunosorbent as-
say (Quidel, Santa Clara, CA). The detection limit was
10 mg/L. The intra-assay coefficients of variations
were 5% (at 40 mg/L), 4% (at 104 mg/L), and 4% (at
155 mg/L). The interassay coefficient of variation was
\6%. Plasma YKL-40 was determined by ELISA in
a large cohort of 8899 subjects, aged 20-95 years, from
the Danish general population [13]. In this cohort,
3130 subjects (1837 women, 1293 men, aged 21-84
years) had no known disease at time of blood sampling
in 1991-1994 and remained healthy and alive during
the 16-year follow-up period. There was no sex differ-
ence in plasma YKL-40 levels. Because plasma YKL-
40 increased exponentially in these healthy subjects
with increasing age, the 95th percentile of plasma
YKL-40 by age was determined. This age correction
of plasma YKL-40 is important to account for, when
plasma YKL-40 is evaluated in patients. The present
study cohorts were therefore divided into subjects with
normal plasma YKL-40 concentrations, that is, below
the age-adjusted 95th percentile, and into subjects
with high plasma YKL-40 concentrations, that is, equal
or above the age-adjusted 95th percentile.Statistics
The inferred haplotypes and linkage disequilib-
rium, expressed as the squared correlation coefficient(R2) quantified between all pairs of biallelic loci,
were estimated using SNPAlyze version 4.0 (Dyna-
com, Yokohoama, Japan). TheHardy-Weinberg equi-
librium was analyzed using gene frequencies obtained
by simple gene counting and the chi-square test with
Yates’ correction. Inferred haplotypes, linkage dis-
equilibrium, and Hardy-Weinberg equilibrium were
analyzed separately for controls, recipients, and do-
nors. Fisher’s exact test and the Kruskal-Wallis test
were used where appropriate. Correlation analyses
were performed using Spearman’s rank correlation
test. Overall survival (OS) was measured from the
time of transplantation until death from any cause. Re-
cipients still alive at the time of analysis were censored
at last follow-up date. Progression-free survival (PFS)
was calculated from date of transplantation to date of
first relapse or death. Recipients who were alive and
in remission were censored at date of last follow-up.
TRM was defined as death in complete remission or
death related to transplantation where it was not pos-
sible to assess disease status before death. Relapse-
related mortality (RRM) was defined as death during
relapsed or progressive disease. Probability of OS
and PFS were estimated by the Kaplan-Meier method,
and comparisons were made with the log-rank test. In
the calculation of cumulative incidences for RRM,
TRM, and GVHD, death before relapse, death with-
out relapse, death without GVHD, and retransplanta-
tion were handled as competing events, where
appropriate in these analyses. Comparisons of cumula-
tive incidences were performed using Gray’s k-sample
test. For the purpose of Cox regression, competing
events were censored. All significant associations be-
tween outcome measures and CHI3L1 genotype and
age-adjusted plasma YKL-40 concentrations were in-
vestigated in multivariate Cox regression models.
The multivariate models were restricted to include
the covariate of interest, recipient age, donor type
(related donor versus unrelated), Kahl score [1] and
GVHD, because of a relatively low number of events.
The presence of grade 2-4 acute and extensive
cGVHD were considered as 1 time varying covariate.
All P values were 2-tailed, and P\ .05 was considered
significant. All statistical analyses were performed us-
ing the R project for statistical computing (http://
www.r-project.org/), except for receiver-operating
characteristic (ROC) analyses (Prism 5 for Windows,
La Jolla, CA).RESULTS
Plasma YKL-40 Concentrations and
Transplantation Outcome
The 3 cohorts differed significantly with regard to
median age (control: 31 years [range: 19-63]; recipi-
ents: 52 years [range: 19-69]; donors: 44 years [range:
1302 Biol Blood Marrow Transplant 17:1299-1307, 2011A. M. Mørup et al.19-68]; P\ .001) and median plasma YKL-40 concen-
trations, with the highest concentrations in recipients
(mean 102.4 ng/mL; standard deviation [SD] 5
128.9; range 9-967), intermediate in donors (mean
57.0 ng/mL; SD 5 42.4; range: 14-240), and lowest
in controls (mean 37.3 ng/mL; SD 5 23.3; range:
20-145). The number of subjects with plasma YKL-
40 concentrations above the age-adjusted 95th percen-
tile was significantly higher in the recipient cohort (32
out of 112 [29%]) compared to the control (7 out of
100 [7%]) and donor cohorts (14 out of 92 [15%])
(recipient cohort versus control cohort: P\ .001; re-
cipient cohort versus donor cohort: P 5 .03), whereas
no significant difference was observed between the
control and donor cohorts (P 5 .10).
The median follow-up time in the transplantation
cohort was 879 days (range: 30-3229) with 5 years
OS, PFS, 1-year cumulative incidence of grade 2-4
aGVHD, and 3 years cumulative incidence of extensive
cGVHD of 53%, 46%, 66%, and 45%, respectively.
The median time from last course of chemotherapy
to conditioning was 173 days (range: 19-3528 days).
No significant differences in number of recipients
with pretransplant YKL-40 concentrations above the
age-adjusted 95th percentile were observed between
disease groups (data not shown). The fraction of recip-
ients not in remission at the time of transplantation
with age-adjusted plasma YKL-40 levels above the
95th percentile was nonsignificantly higher than in
recipients in complete remission (25% versus 33%,
P 5 .41). A similar nonsignificant trend was observed
for the Kahl score, which is a prognostic tool that strat-
ifies recipients into low, intermediate, and high risk of
relapse according to the malignant disease [1]. The
fraction of recipients with high age-adjusted plasma
YKL-40 concentrations approximately doubled when
moving from low-risk disease (16%) to intermediate
(31%) and high risk (34%) (P 5 .27).
When stratified according to the age-adjusted
plasma YKL-40 concentrations, recipients with con-
centrations equal to or above the 95th percentile hadFigure 1. Transplantation outcome stratified according to pretransplantation
Cumulative incidence of relapse-related mortality (A) and Kaplan-Meier estima significantly higher RRM (33% versus 18% at 3
years, P 5 .04), which translated into both a signifi-
cantly lower PFS (38% versus 64% at 3 years, P \
.01) and OS (42% versus 69% at 3 years, P \ .01)
(Figure 1A-1C). The impact of the age adjusted
YKL-40 concentration was most pronounced within
the first year posttransplant. No association between
recipient pretransplant age adjusted YKL-40 concen-
trations and TRM (25% versus 13% at 3 years, P 5
.12) or GVHD (grade 2-4 aGVHD at 1 year: 66% ver-
sus 66%, P 5 .99; grade 3-4 aGVHD at 1 year: 16%
versus 18%; extensive cGVHD at 2 years: 28% versus
37%) was observed. In Cox regression analyses, pre-
transplant recipient plasma YKL-40 concentrations
above or equal to the 95th percentile were also signif-
icant risk factors for RRM, PFS, and OS in both the
univariate model and the multivariate model adjusted
for donor pretransplant age-adjusted YKL-40 concen-
tration, recipient age, donor type, relapse risk (Kahl
score), and presence of GVHD as a time-dependent
variable (Tables 1,2).
Donor plasma YKL-40 concentrations were also
associated with transplantation outcome. Grafts from
donors with YKL-40 concentrations equal to or above
the 95th percentile were associated with a significantly
higher cumulative incidence of grade 2-4 aGVHD at 1
year (93% versus 62%, P\ .01) and lower probability
of OS (48% versus 64% at end of follow-up years,
P 5 .05). In both the univariate and multivariate Cox
regression analyses, elevated donor plasma YKL-40
concentrations were a significant risk factor for devel-
oping grade 2-4 aGVHD, whereas only a trend toward
increased risk of lower OS was observed (Tables 1,2).
No significant associations between plasma YKL-40
concentrations and any other outcome measures
were observed (PFS 48% versus 68%, P 5 .19; RRM
21% versus 17%, P 5 .39; TRM 30% versus 14%,
P5 .11; grade 3-4 aGVHD 29% versus 17%, P5 .32;
extensive cGVHD 44% versus 33%, P 5 .93).
As an alternative to the age-adjusted 95thpercentile,
ROC curve analysis was also performed to determineage-adjusted 95th percentile recipient plasma YKL-40 concentrations.
ates of progression-free survival (B) and overall survival (C).
Table 1. Univariate Cox Regression Analyses According to the Age-Adjusted Plasma YKL-40 Concentrations
Covariate Outcome HR 95% CI P
Recipient pretransplant YKL-40 concentrations Relapse related mortality 2.95 1.27-6.88 .01*
Progression free survival 2.54 1.43-4.50 <.01*
Overall survival 2.79 1.50-5.19 <.01*
Donor YKL-40 concentrations Grade 2-4 acute GVHD 2.35 1.25-4.38 .01*
Overall survival 2.35 0.99-5.53 .05
HR indicates hazard ratio; CI, confidence interval.
HR was analyzed with recipient or donor plasma YKL-40 concentrations < the age-adjusted 95th percentile as reference group (n580; donor n578)
compared to recipients or donors with plasma YKL-40 concentrations $ the age-adjusted 95th percentile (recipient n532; donor n514).
*P < .05.
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RRM, PFS, and OS, the recipient pretransplant YKL-
40 concentration ROC P values were .16, .28, and .03,
with area under the curves (AUC) of 0.60, 0.56, and
0.62, respectively. For grade 2-4 aGVHD and donor
YKL-40 concentrations, the ROC P value was .03,
with an AUC of 0.64. Although 2 of the ROC analyses
yielded significant (P\ .05) results, all the AUCs where
only slightly more than 0.5. The cutoff concentrations
were between 81 and 83 ng/mL (except for grade 2-4
aGVHD, where it was 50 ng/mL) yielding specificities
between 44% and 49% and sensitivities between 70%
and 74%. No further effort was put into pursuing these
cutoff concentrations, as their clinical relevancy and
usefulness would be minimal.
Genetic Variation in CHI3L1
All polymorphisms adhered to the Hardy-
Weinberg equilibrium (P . .05). Moderate to strong
linkage disequilibrium was observed, with squared
correlation coefficients between 0.81-0.94) for
SNP1, SNP2, and SNP4 in all 3 cohorts. Because of
perfect linkage disequilibrium between SNP1 and
SNP3 in the control cohort, recipients and donors
were not genotyped for SNP3. Haplotypes were only
inferred for subjects where all SNPs had been success-
fully genotyped (control cohort, n 5 100; recipients,Table 2. Multivariate Cox Regression Analyses
Covariate
Relapse-Related
Mortality
Pr
HR 95% CI P HR
Recipient pretransplant YKL-40 concentrations,
low vs high$
4.41 1.37-14.14 .01* 2.84
Donor pretransplant YKL-40 concentrations,
low vs high$
4.40 0.93-20.68 .06 2.07
Recipient age 1.00 0.96-1.05 .77 0.99
Donor type, related vs unrelated 0.43 0.14-1.35 .15 1.09
Kahl score [1] 2.70 1.04-7.04 .04* 1.12
Graft-versus-host disease, absence vs presence# 0.18 0.05-0.70 .01* 0.44
HR indicates hazard ratio; CI, confidence interval; NA, not applicable.
$Low is defined as YKL-40 plasma concentrations below the age-adjusted 95th
the age-adjusted 95th percentile. # To adjust the analyses for the absence or pre
and extensive chronic graft-versus-host disease were entered as 1 time-depen
*P < .05.n 5 143; donors, n 5 142) and the same 3 most com-
mon haplotypes, called H1-H3 (H1: T [SNP1], A
[SNP2], T [SNP3], C [SNP4]; H2: H1: A [SNP1], G
[SNP2], G [SNP3], G [SNP4]; andH3:H1: A [SNP1],
A [SNP2], G [SNP3], G [SNP4]) accounted for more
than 98% of the investigated chromosomes (control
cohort: H15 85.5%,H25 14.5%,H35 2.0%; recip-
ients: H15 77.3%,H25 30.3%, H35 1.1%; donors:
H1 5 78.5%, H2 5 18.3%, H3 5 2.1%). There were
no significant differences in the distribution of geno-
types or haplotypes between the 3 cohorts (P . 0.05)
(Supplementary Table S2).
Association between the CHI3L1 Genotype and
YKL-40 Concentration
YKL-40 concentrations were not compared be-
tween controls, recipients, and donors because of dif-
ferences in demographics. However, within each
study cohort, all the investigated polymorphisms dis-
played similar patterns of gene-dose–dependent asso-
ciations with the plasma concentration of YKL-40
(Table 3). Subjects homozygous for the major alleles
had the highest concentrations, whereas subjects het-
erozygous or homozygous for the minor alleles had ei-
ther intermediate or low plasma YKL-40 (Table 3).
The same relationship was evident between the in-
ferred haplotypes and plasma YKL-40 concentrations,Outcome
ogression-Free
Survival Overall Survival
Grade 2-4 Acute Graft-
versus-Host Disease
95% CI P HR 95% CI P HR 95% CI P
1.38-5.87 .01* 3.09 1.39-6.87 .01* 1.51 0.83-2.75 .18
0.83-4.19 .12 2.61 1.00-6.85 .05 2.25 1.16-4.37 .02*
0.96-1.01 .31 1.00 0.97-1.04 .97 0.87 0.60-1.27 .34
0.55-2.18 .80 1.25 0.57-2.76 .57 1.26 0.73-2.15 .59
0.70-1.78 .64 1.07 0.63-1.81 .80 0.98 0.96-1.01 .68
0.20-0.99 .05 0.54 0.22-1.36 .19 NA NA NA
percentile and high as YKL-40 plasma concentrations equal to or above
sence of acute or chronic graft-versus-host disease, both grade 2-4 acute
dent covariate.
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H1) or minor alleles (haplotype H2), had the highest
or lowest concentrations, respectively, whereas sub-
jects carrying any other combinations of minor and
major alleles had intermediate concentrations. The ap-
parent association between gene-dose and YKL-40
plasma concentrations, despite no adjustment for age
having been performed, can be explained by the varia-
tion in age of the subjects within each cohort being
small enough to negate the age effect on plasma con-
centrations.
Association between CHI3L1 Genotype and
Transplantation Outcome
Apart from SNP1 in the recipient cohort, all recipi-
ents homozygous or transplanted with donors homozy-
gous for the minor alleles of SNP1, SNP2, SNP4, and
the H2 haplotype, which were associated with low
YKL-40 plasma concentrations, had OS and PFS of
zero (Supplementary Table S3). These observations
were significant for PFS in the recipients only (Table
4). No obvious convergence between recipient and do-
nor genotypes or haplotypes was observed. Of the 6 re-
cipients who were homozygous for the H2 haplotype,
only 2 were transplanted with donors that also were
H2 homozygous. There was no association between re-
cipient or donor genotypes and RRM, TRM, aGVHD,
or extensive cGVHD (Supplementary Table S3).DISCUSSION
As it has become feasible to treat older and more
medically infirm patients, because of the introduction
of reduced-intensity regimens and better supportive
care, there has been increased interest in developingTable 3. Plasma YKL-40 Concentrations in Controls, Recipients, a
Genotype
Controls
n Mean ± SD, ng/ml (range) P n Mean
100 37 ± 23 (20-145) 112 1
SNP1 T/T 70 40 ± 23 (20-138) 70 1
A/T 26 33 ± 25 (20-145) 37
A/A 4 20 ± 0 (20-20) <.001* 4
SNP2 A/A 74 40 ± 22 (20-138) 73 1
A/G 23 31 ± 26 (20-145) 35
G/G 3 20 ± 0 (20-20) <.001* 3
SNP3 T/T 70 40 ± 23 (20-138)
G/T 26 33 ± 25 (20-145)
G/G 4 20 ± 0 (20-20) <.001*
SNP4 C/C 70 40 ± 23 (20-138) 71 1
C/G 26 32 ± 25 (20-145) 36
G/G 4 20 ± 0 (20-20) <.001* 4
Haplotype H1/H1 69 40 ± 23 (20-138) 69 1
HX/HX 28 32 ± 24 (20-145) 39
H2/H2 3 20 ± 0 (20-20) <.001* 3
SD indicates standard deviation; NA, not applicable; H1/H1, homozygous for h
H2/H2; H2/H2, homozygous for haplotype H2.
*P < .05.tools that can predict outcome pretransplant.
Although prognostic tools based on pretransplant
demographics, such as the HCT comorbidity index
[2,3], have proven very successful, less attention has
been focused on the value of pretransplant analyses of
inflammatory biomarkers. In the pretransplant setting,
CRPhas been associatedwith treatment-related toxicity
[9,10], whereas no association has been observed for
preconditioning concentrations of TNF-a receptor 1
[8], which is a surrogate marker for TNF-a. In this con-
text, we would like to propose the novel inflammatory
biomarkerYKL-40.YKL-40haspreviouslybeenassoci-
atedwithoutcome in a variety of differentmalignant and
inflammatory diseases [11]. Because of its close correla-
tionwith age, it has been suggested that plasmaYKL-40
concentrations shouldbedefined as either lowor high in
relation to age-matchedhealthy controls [12].Twofind-
ings in the current study could encourage using this
approach. First, the correlation with age was evident as
the median YKL-40 concentration was significantly
higher in the older donor cohort compared to the con-
trol, with the high YKL-40 concentrations in the recip-
ients probably being a consequence of contributions
from both age and the malignant disease [11,12].
Second, to establish clinically relevant YKL-40 cutoff
concentrations for different outcomemeasures by using
ROC curves failed, yielding very low sensitivities with
no clinical value. Thus, to avoid the introduction of
bias to our analyses because of a large age span in both
the donor and recipient cohorts, high YKL-40 concen-
trations were defined as being above the 95th percentile
of a large healthyDanish cohort, as previously described
(J.S.J., unpublished results).
In our study, we observed that recipients with pre-
transplant plasma YKL-40 concentrations above the
age-adjusted 95th percentile had a significantly poorernd Donors Stratified According to Genotype
Recipients Donors
± SD, ng/ml (range) P n Mean ± SD, ng/ml (range) P
02 ± 129 (9-967) 92 57 ± 42 (14-240)
18 ± 149 (21-967) 59 65 ± 48 (23-240)
85 ± 82 (18-448) 25 43 ± 21 (20-81)
15 ± 4 (9-17) <.001* 4 22 ± 6 (14-27) .002*
18 ± 146 (21-967) 61 64 ± 48 (23-240)
80 ± 84 (17-448) 23 44 ± 21 (20-81)
14 ± 4 (9-16) <.001* 4 22 ± 6 (14-27) .006*
NA NA
NA NA
NA NA NA NA
19 ± 148 (21-967) 57 67 ± 48 (23-240)
82 ± 83 (18-448) 27 42 ± 20 (20-81)
15 ± 4 (9-17) <.001* 4 22 ± 6 (14-27) .001*
19 ± 150 (21-967) 57 67 ± 48 (23-240)
83 ± 81 (17-448) 27 42 ± 20 (20-81)
14 ± 4 (9-16) .002* 4 22 ± 6 (14-27) <.001*
aplotype H1; HX/HX, any other haplotype combination than H1/H1 or
Table 4. Univariate 5-Year Kaplan-Meier Estimates of Overall Survival and Progression-Free Survival Stratified According to
Recipient or Donor CHI3LI Genotype or Haplotype
CHI3LI genotype
Recipient genotype Donor genotype
N
OS PFS
N
OS PFS
(%) P (%) P (%) P (%) P
SNP1 T/T 89 49 .40 51 .02* 91 51 .17 44 .38
A/T 48 60 51 47 59 50
A/A 8 30 0 6 0 0
SNP2 A/A 93 49 .08 50 .02* 97 53 .19 47 .29
A/G 47 64 45 41 56 45
G/G 6 0 0 6 0 0
SNP4 C/C 88 48 .26 50 .01* 88 53 .25 45 .36
C/G 48 60 45 48 60 50
G/G 7 0 0 6 0 0
Haplotype H1/H1 86 47 .17 50 .02* 87 52 .14 44 .33
HX/HX 51 61 44 49 61 52
H2/H2 6 0 0 6 0 0
OS indicates overall survival; PFS, progression-free survival; H1/H1, homozygous for haplotype H1; HX/HX, any other haplotype combination than
H1/H1 or H2/H2; H2/H2, homozygous for haplotype H2.
*P < .05.
Biol Blood Marrow Transplant 17:1299-1307, 2011 1305YKL-40 in Hematopoietic Cell Transplantationprognosis because of increased RRM, which translated
into both poorer PFS and OS. The impact of pretrans-
plant YKL-40 concentration was most pronounced
within the first year posttransplant, where after survival
curves tended to become parallel. In multivariate anal-
yses, the relationship between YKL-40 and RRM was
independent of type of hematologic cancer and of
other known risk factors for relapse, such as recipient
age, donor type, presence of GVHD, remission status
at the time of transplantation, and relapse risk of the
malignant disease (Kahl score [1]). Although no signif-
icant association between disease severity and YKL-40
concentrations was observed, the number of recipients
with YKL-40 concentrations above the 95th percentile
was higher in the subset not in remission at the time of
transplantation and almost doubled when moving
from recipients with low risk of relapse to intermediate
or high risk [1]. Our observation of an association be-
tween relapse-related outcome measures and YKL-40
is therefore probably not a measure of the efficacy of
the transplantation procedure, but more likely a reflec-
tion of the severity of the underlying disease. Several
lines of evidence have recently linked YKL-40 to onco-
genesis. In gene microarray analyses, increased expres-
sion of YKL-40 mRNA in different carcinoma tissues
have been observed [34-36], and in in vitro tumor
models YKL-40 has been shown to promote tumor
progression and blood vessel formation through the
mitogen-activated protein kinase, which is an impor-
tant pathway in mitogenesis and cell survival
[12,37,38]. In addition to YKL-40’s role in angio-
genesis, its proinflammatory properties may also play
a part in oncogenesis, as the inflammation observed
around malignancies regulates important aspects of
cancer proliferation, differentiation, and invasion [39].
In the current study, an association between donor
plasma YKL-40 concentrations above the age-adjusted95th percentile and grade 2-4 aGVHD was observed.
As YKL-40 has been implicated in activation of den-
dritic cells and inhibition of macrophage andT cell ap-
optosis [23,25], it is not implausible that increased
YKL-40 production adopted from the donor could
augment inflammatory reactions leading to GVHD.
The finding is not supported by an increase in TRM,
and no association between CHI3L1 genotype and
outcome was observed. Thus, even though the obser-
vation of the concentration of an inflammatory marker
in the donor weeks before transplantation being
predictive of outcome is intriguing, there is a risk of
type I error, and further investigations are needed be-
fore it can be ascribed any clinical significance.
The populations were genotyped for 4 polymor-
phisms previously observed to be associatedwith plasma
YKL-40 concentrations [40-42]. All polymorphisms
adhered to theHardy-Weinberg equilibrium in all 3 co-
horts, and genotype frequencies were comparable to
those listed in dbSNP [43]. No differences in genotype
or haplotype distributionwere observed between the re-
cipient cohort and control anddonor cohorts, indicating
that the polymorphisms as such do not play a role in
disease susceptibility. In agreementwithpreviouslypub-
lished data, apparent gene-dose–dependent relation-
ships between all the investigated polymorphisms and
plasma YKL-40 concentrations were observed [40-42].
The lack of correlation between genotypes associated
with high YKL-40 concentrations and outcome is in
contrast to our observation of a relationship between
high YKL-40 concentrations and outcome. However,
as a total of 37 genetic variants have been identified
throughout the entire CHI3L1 gene locus [43], and
with the numerous regulatory elements that control
gene transcription and translation, it is unlikely that
the expressional control of CHI3L1 is limited to the
polymorphisms investigated in the current study. An
1306 Biol Blood Marrow Transplant 17:1299-1307, 2011A. M. Mørup et al.unexpected finding in our studywas that recipients, who
either themselves were homozygous for any of the poly-
morphism minor alleles or were transplanted with do-
nors that were homozygous, all died within the time of
follow-up.As theminor alleleshavebeen shown tobeas-
sociatedwith lowerYKL-40concentrations, thisfinding
is in contrast to the common consensus of low plasma
YKL-40 concentrations being associated with superior
disease outcomes [12,40]. Considering that only 6 to 8
recipients and donors were homozygous for the minor
alleles, the association between genotype and PFS
warrants further investigation in a larger cohort, as
a possible type I error cannot be ruled out.
The biggest limitation of our study is its generaliz-
ability. Although, there is no biological reason for the
YKL-40 effect to be limited to nonmyeloablative
conditioning HCT only, other factors related to
high-dose conditioning, T cell depletion, and the
demographics of the study cohort, may impact the pre-
dictive power of YKL-40. Another limitation of the
study is the size and heterogenic composition of the
cohort, which limits the statistical power of subset
analyses and increases the risk of false positive results.
In conclusion, this study is the first to investigate
the association between plasma YKL-40 concentra-
tions and CHI3L1 genotype in allogeneic HCT. Al-
though the current study is purely descriptive, our
findings suggest a role for recipient pretransplant
plasma YKL-40 concentrations as an independent
risk factor associated with relapse-related outcome
measures. The exact biological functions of YKL-40
are poorly understood, and whether the associations
between plasma YKL-40 concentrations and disease
outcome are causal or just bystander effects is still un-
known. However, an inflammatory biomarker that
defines relapse risk and possibly treatment-related
toxicity could be a valuable tool complementing
clinical risk scores such as the HCT comorbidity
index. Further studies, both clinical, in independent
cohorts, and experimental with analyses of the func-
tional relevance of YKL-40, are needed to confirm
these findings, explain their molecular background,
and possibly establish YKL-40 as an independent
prognostic factor.ACKNOWLEDGMENTS
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